Neurocrine Biosciences (NBIX) Revenue (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Revenue for 16 consecutive years, with $959.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 39.49% year-over-year to $959.0 million; the trailing twelve-month figure through Jun 2026 stood at $3.4 billion (up 34.42% YoY), and the FY2025 full-year result was $2.9 billion, up 21.45% from the prior year.
• Revenue climbed to $959.0 million in Q2 2026 per NBIX's latest filing, from $814.5 million in the prior quarter.
• Across five years, Revenue topped out at $959.0 million in Q2 2026 and bottomed at $310.6 million in Q1 2022.
• Historically, Revenue has averaged $575.8 million across 5 years, with a median of $543.9 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Revenue increased 11.12% in 2025, then surged 42.25% in 2026.
• Over 5 years, Revenue stood at $412.0 million in 2022, then grew by 25.05% to $515.2 million in 2023, then grew by 21.84% to $627.7 million in 2024, then increased by 28.33% to $805.5 million in 2025, then gained by 19.06% to $959.0 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $959.0 million, $814.5 million, and $805.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.